Literature DB >> 3118600

Susceptibility testing of Mycobacterium tuberculosis to pyrazinamide.

M Salfinger1, F M Kafader.   

Abstract

One hundred and sixty clinical isolates of Mycobacterium tuberculois were tested for their sensitivity to pyrazinamide (PZA) using the conventional proportion method (Middlebrook 7H10 agar) and the results compared to the pyrazinamidase (PZase) activity of the strains. The correlation between strains susceptible to PZA and the production of PZase was 99%. None of the isolates were exclusively resistant to PZA. At present the rate of initial PZA resistance in Kanton Zurich is 0.6%.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3118600

Source DB:  PubMed          Journal:  Zentralbl Bakteriol Mikrobiol Hyg A        ISSN： 0176-6724


  4 in total

Review 1.  Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: a systematic review with meta-analyses.

Authors:  Kwok Chiu Chang; Wing Wai Yew; Ying Zhang
Journal:  Antimicrob Agents Chemother       Date:  2011-07-18       Impact factor: 5.191

2.  Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide: comparison of Bactec method with pyrazinamidase assay.

Authors:  M A Miller; L Thibert; F Desjardins; S H Siddiqi; A Dascal
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

3.  Sequencing of the pncA gene in members of the Mycobacterium tuberculosis complex has important diagnostic applications: Identification of a species-specific pncA mutation in "Mycobacterium canettii" and the reliable and rapid predictor of pyrazinamide resistance.

Authors:  Akos Somoskovi; Jillian Dormandy; Linda M Parsons; Michel Kaswa; Khye Seng Goh; Nalin Rastogi; Max Salfinger
Journal:  J Clin Microbiol       Date:  2006-11-29       Impact factor: 5.948

4.  Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method.

Authors:  M Salfinger; L B Heifets
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.